ArticleJournal of neurochemistry2025
Label-Free Proteomic Profiling of the dvls2 (CL2006) Caenorhabditis elegans Alzheimer's Disease (AD) Model Reveals Conserved Molecular Signatures Shared With the Human AD Brain.
Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Alzheimer's disease (AD) is the most common form of dementia, posing significant challenges to cognitive, emotional, social, and financial well-being. The biochemical and molecular pathways associated with AD are complex, making it difficult to study and simulate in patients or through in vitro research. Thus, animal models play a crucial role in investigating the development and progression of AD. One widely used model in neuroscience studies is the free-living nematode Caenorhabditis elegans (C. elegans). The development of transgenic animals has allowed for the construction of the dvls2 (CL2006) C. elegans strain, which constitutively expresses the amyloid beta (Aβ) peptide. This study conducted a proteomic analysis on the dvls2 (CL2006) strain. Also, a cross-species comparative analysis was performed using microarray data from AD patients to identify genes with ontology in the dvls2 (CL2006). A total of 543 proteins were found to be differentially regulated in the dvls2 (CL2006) strain. Furthermore, in the analysis of the human datasets, 397 upregulated and 767 downregulated genes were identified. The differentially expressed genes (DEGs) were analyzed in Ortholist to identify their orthologs in C. elegans. Then, the orthologous genes in the dvls2 (CL2006) model were compared to the proteomic data, resulting in the identification of 29 upregulated and 24 downregulated proteins (DEPs). Functional enrichment analysis of DEPs revealed terms related to pyruvate, glucose, and glutamate metabolism, in addition to binding activities to unfolded proteins and ligases, highlighting the upregulation of chaperone and ubiquitination-associated proteins. Protein-protein network (PPI) was performed for the human DEGs and DEPs of dvls2 (CL2006). Topological analyses of the networks were performed, revealing the following C. elegans hub proteins: EEF-2, ALH-13, ENOL-1, RPL-2, TPI-1, CTS-1, RPL-9, RPL-23, CCT-1, and RPS-8. eEF-2 was identified as a key regulator of the human AD PPI and dvls2 (CL2006). Modules were analyzed in the networks, and the presence of key regulators was identified. This study provides the first proteomic characterization of the AD model dvls2 (CL2006) and a cross-species comparative analysis with data from AD individuals, supporting the use of dvls2 (CL2006) in AD studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.